» Articles » PMID: 19088204

Trop2 Identifies a Subpopulation of Murine and Human Prostate Basal Cells with Stem Cell Characteristics

Overview
Specialty Science
Date 2008 Dec 18
PMID 19088204
Citations 209
Authors
Affiliations
Soon will be listed here.
Abstract

The epithelium of the adult prostate contains 3 distinct cell types: basal, luminal, and neuroendocrine. Tissue-regenerative activity has been identified predominantly from the basal cells, isolated by expression of CD49f and stem cell antigen-1 (Sca-1). An important question for the field is whether all basal cells have stem cell characteristics. Prostate-specific microarray databases were interrogated to find candidate surface antigens that could subfractionate the basal cell population. Tumor-associated calcium signal transducer 2 (TACSTD2/Trop2/M1S1/GA733-1) was identified because it was enriched after castration, in prostate sphere cells and in the basal fraction. In the murine prostate, Trop2 shows progenitor characteristics such as localization to the region of the gland proximal to the urethra and enrichment for sphere-forming and colony-forming cells. Trop2 subfractionates the basal cells into 2 populations, both of which express characteristic basal cell markers by quantitative PCR. However, only the basal cells expressing high levels of Trop2 were able to efficiently form spheres in vitro. In the human prostate, where Sca-1 is not expressed, sphere-forming progenitor cells were also isolated based on high expression of Trop2 and CD49f. Trop2-expressing murine basal cells could regenerate prostatic tubules in vivo, whereas the remaining basal cells had minimal activity. Evidence was found for basal, luminal, and neuroendocrine cells in prostatic tubules regenerated from Trop2(hi) basal cells. In summary, functionally distinct populations of cells exist within the prostate basal compartment and an epithelial progenitor can give rise to neuroendocrine cells in vivo.

Citing Articles

Cellular cartography reveals mouse prostate organization and determinants of castration resistance.

Cho H, Zhang Y, Tien J, Mannan R, Luo J, Narayanan S bioRxiv. 2025; .

PMID: 39763898 PMC: 11703157. DOI: 10.1101/2024.12.27.630532.


Prostate cancer stem cells: an updated mini-review.

Zhou K, Lu H, Zhang J, Shen Q, Liu P, Xu Q J Cancer. 2024; 15(20):6570-6576.

PMID: 39668824 PMC: 11632998. DOI: 10.7150/jca.100604.


Efficacy and safety of sacituzumab govitecan Trop-2-targeted antibody-drug conjugate in solid tumors and UGT1A1*28 polymorphism: a systematic review and meta-analysis.

Sultana R, Chen S, Lim E, Dent R, Chowbay B BJC Rep. 2024; 2(1):85.

PMID: 39528547 PMC: 11554802. DOI: 10.1038/s44276-024-00106-1.


Prostate cancer stem cells and their targeted therapies.

Su H, Huang L, Zhou J, Yang G Front Cell Dev Biol. 2024; 12:1410102.

PMID: 39175878 PMC: 11338935. DOI: 10.3389/fcell.2024.1410102.


A Marine Collagen-Based 3D Scaffold for In Vitro Modeling of Human Prostate Cancer Niche and Anti-Cancer Therapeutic Discovery.

Song W, Lim Y, Kim J, Kang H, Lee C, Rajbongshi L Mar Drugs. 2024; 22(7).

PMID: 39057404 PMC: 11277582. DOI: 10.3390/md22070295.


References
1.
Xin L, Lukacs R, Lawson D, Cheng D, Witte O . Self-renewal and multilineage differentiation in vitro from murine prostate stem cells. Stem Cells. 2007; 25(11):2760-9. DOI: 10.1634/stemcells.2007-0355. View

2.
Baeuerle P, Gires O . EpCAM (CD326) finding its role in cancer. Br J Cancer. 2007; 96(3):417-23. PMC: 2360029. DOI: 10.1038/sj.bjc.6603494. View

3.
Rumpold H, Heinrich E, Untergasser G, Hermann M, Pfister G, Plas E . Neuroendocrine differentiation of human prostatic primary epithelial cells in vitro. Prostate. 2002; 53(2):101-8. DOI: 10.1002/pros.10129. View

4.
Chuang C, Wu T, Tsao K, Liao S . Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer. J Formos Med Assoc. 2003; 102(7):480-5. View

5.
Abrahamsson P . Neuroendocrine differentiation in prostatic carcinoma. Prostate. 1999; 39(2):135-48. DOI: 10.1002/(sici)1097-0045(19990501)39:2<135::aid-pros9>3.0.co;2-s. View